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ofﬁ cial Sentinel Network. The advantage of the LPD data is that its trends are available 
almost in real time, whereas the active reporting of the doctors of Sentinel Network 
is done on a weekly basis. However, the LPD trends lack of geographical precision 
because of the censorship of the post codes of patient during the de-identiﬁ cation 
process. We recommend a combined use of LPD and Sentinel Networks in the follow 
up of future epidemics.
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OBJECTIVES: The medical care of HIV/AIDS patients is becoming increasingly 
complex involving a host of issues including medication management, co-infections, 
cardiovascular risk factors and patient characteristics. This analysis used a set of 
patient characteristics and treatment patterns to explore potential predictors of HIV 
progression. METHODS: Aids Community Services of Western New York provides 
primary medical care services to approximately 600 HIV/AIDS patients yearly in 
WNY. A total of 1128 patients, receiving care from August 2006 through June 2010 
were included in the analysis. The patient characteristics, health indicators, medication 
information and risk factors were used as potential predictors of disease progression. 
Disease progression was measured by the surrogate endpoints of CD4 counts and 
CD4/CD8 ratio values. a mixed model with a repeated structure was ﬁ t to the data 
set (with a signiﬁ cance level of 0.05). RESULTS: The patient population was com-
prised of 757 men and 371 women; the average age of the population was 44 years. 
The population sampled was predominantly Caucasian, African American and His-
panic (39%, 39%, and 19%). The most common HIV medications administered to 
these patients were ritonavir, a tanofovir/emtricitabine combination, atazanavir and 
a lopinavir/ritonavir combination. The most common risk factors in this population 
were male with male sex, heterosexual sex and IV Drug use (27%, 15%, and 9%). 
For the multivariate model utilizing the CD4 counts as the outcome variable, only 
medications and cardiovascular risk factors were signiﬁ cant predictors. For the mul-
tivariate model utilizing the CD4/CD8 ratio as the outcome variable, only the HIV 
risk factors and medications were signiﬁ cant predictors. Both models achieved global 
statistical signiﬁ cance. CONCLUSIONS: The management of HIV/AIDS is an increas-
ingly complex problem which requires constant advances in both research and prac-
tice. This exploratory analysis was able to identify signiﬁ cant relationships between 
patient characteristics, treatment patterns and measures of disease progression. 
INFECTION – Cost Studies
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OBJECTIVES: Madrid Health Authorities decided the introduction of Pneumococcal 
Conjugate Vaccine (PCV) as systematic use for infants in November 2006 (3 + 1 
pattern; 2, 4, 6 + 18 months). Recently, a ﬂ awless transition to PCV13 has been 
recommended. This study was aimed to assess the budget impact of an additional 
catch-up vaccination strategy from the age of 19 to 60 months. METHODS: A one-
year budget impact model has been developed stratifying population by age groups 
(19 to 24, 25 to 36, 37 to 48 and 49 to 60 months) and diseases (IPD and Non-IPD). 
Clinical data, PCV13 serotype coverage and disease related costs were based on 
published data. Model was built up under regional health care system perspective and 
assumed 80% of coverage for PCV13. Indirect effect was not considered. All costs 
were expressed in c2010. RESULTS: The model predicts that the implementation of 
a catch-up vaccination program with PCV13 in the RM would be a cost saving 
measure in infant groups from 19 to 36 months due to disease burden reduction caused 
by the 6 PCV13 additional serotypes. Globally, 49.6% of IPD, 58.9% of OMA 
and 47.1% of out-patient pneumonia cases would be prevented in these groups. 
CONCLUSIONS: Based on this health economic evaluation, the inclusion of a catch-
up program with PCV13 in the RM would be an efﬁ cient measure. Model results 
showed that a PCV13 catch-up dose would have a high impact on pneumococcal 
disease prevention, avoiding its related costs.
PIN8
COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON (ALFA-2B) 
WITH RIBAVIRIN COMPARED WITH PEGINTERFERON (ALFA-2A) WITH 
RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C
Omelyanovsky VV, Avksentieva MV, Krysanov I, Ivakhnenko O
Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Moscow, 
Russia
OBJECTIVES: Combination therapy with pegylated interferon with ribavirin is the 
standard of care for the treatment of chronic hepatitis C infection. This analysis 
compares the cost efﬁ cacy of of combined antiviral therapy with peginterferon 
alfa—2b with ribavirin compared peginterferon alfa—2Ü with ribavirin for treatment 
at patients with a hepatitis C infection counting for 1 patient. METHODS: A decision 
analysis model was constructed from the viewpoint of a managed care organization 
to compare Peg-2b plus RBV (1.5 mcg per kilogram per week plus RBV 1000 mg per 
day) and Peg-2a plus RBV (180 mcg per week plus RBV 1000 mg per day). For 
purposes of this analysis, distribution on genotypes and treatment duration and efﬁ -
cacy data were obtained from the published literature. The positive predictive value 
was calculated for each treatment group for genotype 1, which is determined from 
the values for early virologic response and sustained viral response. Genotype 2 and 
genotype 3 were assumed to be treated for 24 weeks. RESULTS: Antiviral therapy of 
combined antiviral therapy with peginterferon alfa—2b with ribavirin is economically 
more favourable in comparison with therapy in a combination peginterferon alfa—2Ü 
with ribavirin and taking into account efﬁ ciency of treatment the difference indicator 
makes c3293 thousand on 1 patient. CONCLUSIONS: Antiviral therapy of combined 
antiviral therapy with peginterferon alfa—2b with ribavirin is economically more 
favourable in comparison with therapy in a combination peginterferon alfa—2Ü with 
ribavirin and taking into account efﬁ ciency of treatment the difference indicator makes 
c3293 thousand on 1 patient.
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BACKGROUND: The quadrivalent (6,11,16,18) HPV vaccine has been approved in 
many countries for prevention of cervical cancer, vulvar/vaginal pre-cancers, and 
genital warts in women age 9 to 26 years. OBJECTIVES: To assess the health and 
economic impact of the quadrivalent (6,11,16,18) HPV vaccine in Japan. METHODS: 
A published mathematical model of the transmission dynamics of HPV infection and 
disease was adapted for Japan. Model inputs were used from Japan or the Asia/Paciﬁ c 
region when available; otherwise, the default values in the original model were used. 
Maintaining current cervical cancer screening practices in Japan, we evaluated two 
strategies: routine vaccination of females by age 12 (S1), and S1 combined with a 
temporary (5 years) female catch-up program for age 12–24 years (S2). The vaccine 
coverage rates were 80% for the routine and 50% for the catch-up vaccination pro-
grams. RESULTS: The most effective strategy was S2. Using this strategy over 100 
years in the population of Japan, the estimated cumulative percent reduction in inci-
dent HPV 6/11/16/18-related genital warts-female, genital warts-male, cervical 
intraepithelial neoplasia (CIN) grade 1, CIN 2/3, and cervical cancer cases was 90% 
(2,113,723 cases), 86% (2,082,637 cases), 72% (263,406 cases), 71% (1,328,366 
cases), and 58% (323,145 cases), respectively. The cost-effectiveness ratios were US$ 
12,434 (weekly dominated), and US$ 12,058 per quality-adjusted life-years (QALY) 
gained for S1 and S2 compared with no vaccination, respectively. CONCLUSIONS: 
In Japan, vaccination of females age 12–24 years with a quadrivalent (6,11,16,18) 
HPV vaccine can reduce the incidence of cervical cancer, CIN, and genital warts at a 
cost per QALY ratio within the range typically regarded as cost-effective.
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OBJECTIVES: A Phase III study of doripenem versus imipenem in VAP (DORI-10) 
has shown a statistically signiﬁ cant reduction in length of stay (LOS) and mechanical 
ventilation (MV) duration with doripenem. This study estimated expected hospital 
cost versus G-DRG payment for a patient treated with doripenem versus imipenem. 
METHODS: From both DORI-10 trial arms, and for nine categories of post-random-
ization MV duration, we obtained percentages of patients per group and median LOS 
by type of ward (ICU with vs. w/out MV, general ward). One clinical expert provided 
ICD and OPS codes for four likely patient proﬁ les, and another expert on intensive 
care severity (TISS/SAPS). Using the Muenster Webgrouper, we determined G-DRG 
weights when simultaneously varying MV duration and intensive care severity (8–890 
code). Per treatment arm and for each MV subgroup, the appropriate G-DRG weight 
was selected based on the selected proﬁ le, total MV duration, 8–980 code, and total 
LOS. Using the distribution of patients by category, a weighted G-DRG was calculated 
for each arm, and G-DRG weight was multiplied by the 2010 base value (c2936) to 
yield expected G-DRG payment. Within each arm, we calculated cost per MV category 
(hospital per diem plus antibiotic therapy) as well as a weighted cost. RESULTS: 
Expected cost for a patient receiving doripenem was c30,183 vs. c32,549 for imipe-
nem. Expected revenue reduction ranged from c2084 to c2428 across 4 scenarios. Net 
budget impact of the introduction of doripenem ranged from −c85 to c282, showing 
that revenue reduction may be more than offset by cost reduction. CONCLUSIONS: 
For a patient receiving doripenem instead of imipenem, reduced hospitalization costs 
more than offset reduced G-DRG revenue in a wide range of cases. In addition, less 
time on the ventilator can improve patient outcomes (including quality-of-life), and 
frees up ICU bed-days, allowing more patients to be treated.
